Skip to content

Study · Animal study (in vivo) · rat · 2019

8 results

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.

Basalay MV, Davidson SM, Yellon DM

Cardiovascular drugs and therapy1 Dec 2019Cited by 55 (Europe PMC)

PMID31721014 (opens in a new tab)PMCIDPMC6994526 (opens in a new tab)DOI10.1007/s10557-019-06915-8 (opens in a new tab)PepBankPUB-31721014
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

PurposeA substantial number of ischaemic stroke patients who receive reperfusion therapy in the acute phase do not ever fully recover. This reveals the urgent need to develop new adjunctive neuroprotective treatment strategies alongside reperfusion therapy. Previous experimental studies demonstrated the potential of glucagon-like peptide-1 (GLP-1) to reduce acute ischaemic damage in the brain. Here, we examined the neuroprotective effects of two GLP-1 analogues, liraglutide and semaglutide.MethodsA non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO). Liraglutide or semaglutide was administered either i.v. at the onset of reperfusion or s.c. 5 min before the onset of reperfusion. Infarct size and functional status were evaluated after 24 h or 72 h of reperfusion.ResultsLiraglutide, administered as a bolus at the onset of reperfusion, reduced infarct size by up to 90% and improved neuroscore at 24 h in a dose-dependent manner, following 90-min, but not 120-min or 180-min ischaemia. Semaglutide and liraglutide administered s.c. reduced infarct size by 63% and 48%, respectively, and improved neuroscore at 72 h following 90-min MCAO. Neuroprotection by semaglutide was abolished by GLP1-R antagonist exendin(9-39).ConclusionInfarct-limiting and functional neuroprotective effects of liraglutide are dose-dependent. Neuroprotection by semaglutide is at least as strong as by liraglutide and is mediated by GLP-1Rs.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 90 min of middle cerebral artery occlusion, liraglutide given as a bolus at reperfusion reduced infarct size by up to 90% in a dose-dependent manner.

    In plain wordsIn rats with a stroke model, liraglutide given at reperfusion cut the size of brain damage by up to 90%.

    Peptide
    Liraglutide
    Outcome
    DecreaseInfarct size after 90-min MCAO
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    Infarct size reduction
    ≤ 90%
    90-min MCAO

    Source sentences

    Summary
    Liraglutide, administered as a bolus at the onset of reperfusion, reduced infarct size by up to 90% and improved neuroscore at 24 h in a dose-dependent manner, following 90-min, but not 120-min or 180-min ischaemia.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 90 min of middle cerebral artery occlusion, liraglutide given as a bolus at reperfusion improved neuroscore at 24 h in a dose-dependent manner.

    In plain wordsIn rats with a stroke model, liraglutide given at reperfusion improved the neurological score at 24 hours, more with higher doses.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedNeuroscore at 24 h after 90-min MCAO
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Liraglutide, administered as a bolus at the onset of reperfusion, reduced infarct size by up to 90% and improved neuroscore at 24 h in a dose-dependent manner, following 90-min, but not 120-min or 180-min ischaemia.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, liraglutide given as a bolus at reperfusion was not protective after 120-min or 180-min ischaemia.

    In plain wordsIn rats with a stroke model, liraglutide given at reperfusion gave no protection after longer blockage of 120 or 180 minutes.

    Peptide
    Liraglutide
    Outcome
    No significant changeInfarct size and neuroscore after 120-min or 180-min MCAO
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    following 90-min, but not 120-min or 180-min ischaemia.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 90-min middle cerebral artery occlusion, subcutaneous liraglutide reduced infarct size by 48%.

    In plain wordsIn rats with a stroke model, liraglutide under the skin reduced the size of brain damage by 48%.

    Peptide
    Liraglutide
    Outcome
    DecreaseInfarct size after 90-min MCAO, subcutaneous
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Infarct size reduction
    48%
    liraglutide s.c.

    Source sentences

    Summary
    Semaglutide and liraglutide administered s.c. reduced infarct size by 63% and 48%, respectively, and improved neuroscore at 72 h following 90-min MCAO.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 90-min middle cerebral artery occlusion, subcutaneous semaglutide reduced infarct size by 63%.

    In plain wordsIn rats with a stroke model, semaglutide under the skin reduced the size of brain damage by 63%.

    Peptide
    Semaglutide
    Outcome
    DecreaseInfarct size after 90-min MCAO, subcutaneous
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Measurements

    Infarct size reduction
    63%
    semaglutide s.c.

    Source sentences

    Summary
    Semaglutide and liraglutide administered s.c. reduced infarct size by 63% and 48%, respectively, and improved neuroscore at 72 h following 90-min MCAO.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 90-min middle cerebral artery occlusion, subcutaneous liraglutide improved neuroscore at 72 h.

    In plain wordsIn rats with a stroke model, liraglutide under the skin improved the neurological score after 72 hours.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedNeuroscore at 72 h after 90-min MCAO, subcutaneous
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Semaglutide and liraglutide administered s.c. reduced infarct size by 63% and 48%, respectively, and improved neuroscore at 72 h following 90-min MCAO.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with 90-min middle cerebral artery occlusion, subcutaneous semaglutide improved neuroscore at 72 h.

    In plain wordsIn rats with a stroke model, semaglutide under the skin improved the neurological score after 72 hours.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedNeuroscore at 72 h after 90-min MCAO, subcutaneous
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Semaglutide and liraglutide administered s.c. reduced infarct size by 63% and 48%, respectively, and improved neuroscore at 72 h following 90-min MCAO.
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rats, the GLP-1 receptor antagonist exendin(9-39) abolished the neuroprotection by semaglutide.

    In plain wordsIn rats, blocking the GLP-1 receptor with exendin(9-39) removed the protection that semaglutide gave.

    Peptide
    Semaglutide
    Outcome
    No significant changeNeuroprotection with GLP-1R antagonist exendin(9-39)
    Study

    ratn: not reported in source

    Non-diabetic rat model of middle cerebral artery occlusion
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Neuroprotection by semaglutide was abolished by GLP1-R antagonist exendin(9-39).
    1 context sentence
    Summary · context
    A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.